SCHEMBL1781437

SCHEMBL1781437

CCOC(=O)n1nc(NC(=O)c2ccc(N3CCN(C)CC3)cc2NC(=O)c2ccco2)c2cc(C(=O)OC(C)(C)C)sc21

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BTK Q06187 2/20 0.45
KMT2A Q03164 2/20 0.39
MEN1 O00255 1/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
NPC1 O15118 3/20 0.38
RAB9A P51151 3/20 0.38
LMNA P02545 1/20 0.38
INSR P06213 3/20 0.37
ALK Q9UM73 3/20 0.37
IGF1R P08069 2/20 0.37
KDM4E B2RXH2 5/20 0.37
ALDH1A1 P00352 4/20 0.37
HPGD P15428 2/20 0.37
TSHR P16473 1/20 0.37
MAPK1 P28482 1/20 0.37
MAPT P10636 4/20 0.36
HSD17B10 Q99714 2/20 0.36
USP2 O75604 1/20 0.36
TP53 P04637 1/20 0.36
ATM Q13315 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1778750 0.92 BTK (0.45) BTKKMT2AMEN1SMN1; SMN2NPC1
SCHEMBL1779991 0.89 AURKA (0.45) BTKKMT2AMEN1SMN1; SMN2NPC1
SCHEMBL1778613 0.88 BTK (0.40) BTKKMT2AMEN1INSRALK
SCHEMBL1777250 0.87 IGF1R (0.44) BTKINSRALKIGF1RAURKA
SCHEMBL1778870 0.87 CSF1R (0.40) BTKKMT2AMEN1INSRALK
SCHEMBL1780033 0.87 KDM4E (0.44) KMT2AMEN1SMN1; SMN2NPC1RAB9A
SCHEMBL1779266 0.86 WDR5 (0.37) INSRALKIGF1RAURKA
SCHEMBL742604 0.86 KDM4E (0.46) KMT2AMEN1SMN1; SMN2NPC1RAB9A
SCHEMBL1780302 0.85 WDR5 (0.35) BTKLMNAINSRALKIGF1R
SCHEMBL1777877 0.85 PDE7A (0.43) BTKLMNAINSRALKIGF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1904503-B1 1H-THIENO[2,3-C]-PYRAZOLE COMPOUNDS USEFUL AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES SRL (IT) 2013-11-06 EP disclosed
US-7943654-B2 1H-thieno[2,3-c]pyrazole compounds useful as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2011-05-17 US disclosed
US-20090149457-A1 1H-Thieno[2,3-c]Pyrazole Compounds Useful as Kinase Inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2009-06-11 US disclosed
EP-1904503-A1 1H-THIENO[2,3-C]-PYRAZOLE COMPOUNDS USEFUL AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.r.l. (IT) 2008-04-02 EP disclosed
WO-2007009898-A1 1H-THIENO[2,3-C]PYRAZOLE COMPOUNDS USEFUL AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2007-01-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090149457-A1 1H-Thieno[2,3-c]Pyrazole Compounds Useful as Kinase Inhibitors CCNH, PDK1, MAP3K5 BTK 940/4885KMT2A 2397/4885MEN1 4395/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.